GSK Plc shares surged after the UK pharma company agreed to pay as much as $2.2 billion to resolve about 80,000 US court ...
WJET Erie on MSN2d
Drugmaker to settle nearly 80,000 Zantac lawsuits for up to $2.2 billionUK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...
GlaxoSmithKline (GSK) saw its shares jump more than 6% after the pharmaceutical giant announced a settlement of up to $2.2 ...
GSK has agreed to pay $2.2bn to settle about 80,000 Zantac lawsuits in the US. In a statement released after the close of ...
In 2020, the Food and Drug Administration requested the withdrawal of Zantac from the market following an investigation ... That deal is still subject to final approval from the U.S. Department ...
The concerns surrounding Zantac also prompted UK health authorities to advise doctors in 2019 to cease prescribing specific formulations of the drug as a precautionary measure. Reports indicated that ...
GSK has opted to settle a key lawsuit in its defence against claims that its Zantac drug caused cancer ... Nevertheless, the drug was pulled off the market in 2020. There had been speculation ...
On Wednesday, GSK plc (NYSE:GSK) reached agreements with ten plaintiff firms representing approximately 80,000 Zantac product ...
The US Food and Drug Administration asked companies producing Zantac to remove all ranitidine-based drugs from the US market in 2020 ... as other drugmakers are still facing trials, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback